Table 2.
COVID-19 vaccines authorized for emergency use† or in phase 3 development in the US as of October 20, 2021.
| Vaccine type | Name | Primary developers | Country of origin | Date of approval or emergency use authorization in the US and EU |
|---|---|---|---|---|
| mRNA based | BNT162b2 | Pfizer-BioNTech | Multinational | US: Approval August 23, 2021 EU: December 21, 2020 |
| mRNA based | BNT162b1 | Pfizer-BioNTech | Multinational | US: N/A (Phase 3 clinical trials) EU: N/A (Phase 2 clinical trials) |
| mRNA based | mRNA-1273 | Moderna | US | US: EUA December 18, 2020 EU: January 6, 2021 |
| DNA based | INO-4800 | Inovio | US | US: N/A (Phase 3 clinical trials) EU: N/A |
| Adenovirus | AZD1222 | AstraZeneca | UK | US: N/A (Phase 3 clinical trials) EU: January 29, 2021 |
| Non-replicating viral vector | JNJ-78436735 (Ad26.COV2.S) | Johnson & Johnson/Janssen | US | US: February 27, 2021 EU: March 11, 2021 |
| Nanoparticle | NVX-CoV2373 | Novavax | US, Mexico | US: N/A (Phase 3 clinical trials) EU: December 20, 2021 |
| Plant-based virus-like particle | CoVLP | Medicago | US, Canada | US: N/A (Phase 3 clinical trials) EU: N/A |
EUA, Emergency use authorization; N/A, not applicable.